American Society of Clinical Oncology’s Gastrointestinal Cancer Symposium (GIASCO) 2019: How you can stay up-to-date on the research from home

It seems like just yesterday that the Fight Colorectal Cancer (Fight CRC) team was preparing for the 2018 American Society of Clinical Oncology’s Gastrointestinal Cancer Symposium (GIASCO) in San Francisco, Calif. One year later, here we are again gearing up for an exciting week full of research, collaboration, and education.

This year, Fight CRC will host another Immunotherapy Workgroup meeting. In this meeting, we will get the latest updates in colon and rectal cancer research, and we will work alongside researchers and advocates to identify next steps.

On-site Plans and How to Stay Connected from Home

If you are attending GIASCO, don’t forget to stop by booth #42!

  • Our team will be distributing a wide variety of patient education materials to health care professionals so that they can share them with the patients they serve. You, too, can share resources! Become a distributor to make sure CRC patients get the resources they need at the right time.
  • Our team will be attending sessions and meeting with leaders in the field. Following the conference, we will update YOU in our Post-GI ASCO Webinar. Register for the webinar here. Even you can’t attend live, it’s important to register so that we can send you the recorded webinar the next day.
  • Facebook LIVE! Fight CRC Research Advocates will be interviewing Drs. Cathy Eng and Dustin Deming. Head over to Fight CRC’s Facebook page during these times to catch us with the researchers!
    • Jan 17th 7:30 am PST: We will be interviewing Dr. Cathy Eng on some of the most interesting trials and updates that at the conference – and we’ll be discussing the importance of HER-2 and Neu testing
    • Jan 18th 9:15 am PST: Dr. Dusty Deming will be filling us in on his current research, what’s happening at GIASCO, what patients need to know, and how his work is contributing to moving the state of the science forward in colorectal cancer research.
  • Instagram and Twitter Takeover: Follow Reese Garcia (@ReeseFCRC), Sharyn Worrall (@SharynFCRC), and FightCRC (@FightCRC) on Twitter, and follow Fight CRC’s Instagram Account. We will be posting updates throughout the duration of the conference. Here are just a few specific abstracts we will be keeping our eyes on:
    • Abstract 688: Updated results of the BEACON CRC safety lead-in: Encorafenib (ENCO) +binimetinib (BINI) + cetuximab (CETUX) for BRAFV600E-mutant metastatic colorectal cancer (mCRC). First Author: Scott Kopetz, MD, PhD
    • Abstract 680: A phase Ib study of pembrolizumab (Pem) in combination with stereotactic body radiotherapy (SBRT) for resectable liver metastatic colorectal cancer (CRC). First Author: Anita Ahmed Turk, MD, BA
    • Abstract 613: A randomized phase II study comparing oral S-1 plus a 24-hour infusion of irinotecan (Iri) and bevacizumab (Bev) with FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer (MCRC). First Author: Sotaro Sadahiro, MD, PhD
    • Abstract 595: Guanylate cyclase c (GUCY2C) as a preventative and therapeutic target in colorectal cancers (CRCs) arising through divergent genomic pathways. First Author: Babar Bashir, MBBS
    • Abstract 703: Pharmacogenomics-guided chemotherapy and supportive care for patients with metastatic colorectal cancer. First Author: Pashtoon Murtaza Kasi, MD, MSc

Post-GIASCO Blog and Webinar

Keep your eyes out for a post-GIASCO blog, and be sure to register for our webinar with Drs. Dustin Deming and Nataliya Uboha from the University of Wisconsin who will be covering all of the highlights for colon and rectal cancer patients!

Fight CRC is excited to attend GIASCO 2019 to learn and engage with researchers, patients and colorectal cancer champions this week. We’ll continue pushing for research to empower and educate our community of fighters and survivors.

Would you like to donate to research? 100% of the funds’ Fight CRC raises for research goes directly to research!

  • Was this information helpful?
  • yesno

Leave a Reply

Your email address will not be published. Required fields are marked *